Author: Tely Publisher

Introduction

In the ever-evolving landscape of medical research, Contract Research Organizations (CROs) have emerged as vital players, bridging the gap between innovative therapies and their successful market entry. These organizations offer a spectrum of specialized services that streamline clinical trials, from site feasibility and patient recruitment to regulatory compliance and data management.

As the demand for efficient and effective clinical research intensifies, particularly in regions like Colombia—which boasts unique advantages for first-in-human trials—the role of CROs becomes increasingly significant. This article delves into the essential functions of CROs, evaluates the criteria for ranking the top organizations in the field, and highlights key players such as:

• IQVIA
• Parexel
• Medpace

showcasing their contributions to advancing healthcare solutions and improving patient outcomes across the globe.

1. Understanding Contract Research Organizations (CROs): An Overview

(CROs) act as essential collaborators in the pharmaceutical, biotechnology, and medical device industries, providing specialized outsourced services that include a thorough process for progressing medical device evaluations. They play an essential role in:

1. Site feasibility
2. Investigator selection
3. Start-up approvals
4. Monitoring

This ensures adherence to regulatory standards and facilitates the development of innovative therapies. Among the extensive services they provide are:

• Study design
• Data management
• Regulatory submissions
• Ongoing monitoring

Each is vital for the successful execution of research projects.

Significantly, Colombia offers competitive benefits for , including:

• R&D tax incentives

This environment is further enhanced by the collaboration between bioaccess™ and Caribbean Health Group, which aims to position Barranquilla as a leading destination for medical trials in Latin America, supported by Colombia’s Minister of Health. This governmental support highlights the dedication to making Barranquilla an appealing center for clinical studies.

By leveraging the expertise of the biggest , sponsors can focus on their core competencies while benefiting from enhanced efficiency and reduced costs in the study process. As David Maislin aptly states,

Their expertise and commitment to patient-focused studies ensure they will continue delivering .

Notably, PSI, a fast-growing CRO, received the CRO Leadership Awards for Expertise, Quality, and Reliability in June 2023, underscoring its commitment to excellence in the industry.

The global influence of the biggest , such as IQVIA, Thermo Fisher, and Parexel International, enhances their importance, enabling them to execute studies across various populations and navigate international regulations. This capability not only provides a competitive edge but also aligns with the needs of a rapidly evolving healthcare landscape, where an estimated 20 million new cancer cases were diagnosed in 2022. The capacity to reach diverse patient groups guarantees that investigations are performed ethically and with cultural awareness, thus improving the overall quality and significance of medical inquiries.

2. Criteria for Ranking the Top Contract Research Organizations

The ranking of (CROs) is determined by a comprehensive evaluation of multiple criteria, including:

1. Revenue performance
2. Market share
3. Global reach

, as it reflects the effectiveness of the CRO in meeting the needs of its partners. As IBISWorld notes, as it directly influences the rankings of CROs and their reputation in the industry.

Furthermore, organizations are evaluated based on their service offerings, particularly in such as:

• Feasibility studies
• Site selection
• Compliance reviews
• Import permits
• Reporting

In 2024, for instance, PSI has been recognized for its exceptional performance, receiving CRO Leadership Awards for six consecutive years, highlighting its expertise, quality, and reliability. Additionally, TFS received a Silver Rating from EcoVadis in 2024, placing it in the top 15% for , which underscores the importance of sustainability in the evaluation criteria.

Adaptability to evolving industry demands plays a vital role in these rankings, ensuring that the biggest not only lead in size but also significantly contribute to advancing , enhancing patient outcomes, and positively impacting local economies through job creation and economic growth. The biggest in the CRO industry offer essential study services on a contract basis to the pharmaceutical and biotechnology sectors, playing a vital role in supporting drug and medical device development through various study services. This encompasses detailed procedures such as:

• The review and feedback on research documents to comply with country requirements
• Obtaining for
• Ongoing monitoring and reporting of research status and adverse events

This multifaceted approach to evaluation underscores the importance of both quantitative and qualitative factors in determining the top performers in the CRO landscape.

3. IQVIA: Leading the Charge in Clinical Research

As one of the biggest in the healthcare field, IQVIA utilizes its vast data analysis and advanced technology to provide thorough solutions for its clients. Our service capabilities include:

2. Selection of research locations and principal investigators
3. Compliance reviews—including feedback on documents to ensure adherence to country requirements
4. and health ministry approvals

This ensures that all phases of are supported.

As one of the biggest , this organization seamlessly transitions from preclinical studies to post-market surveillance, with methodologies that incorporate real-world evidence alongside advanced analytics, allowing for that ultimately lead to improved patient outcomes. In 2023, there were 24 in the U.S., highlighting the dynamic nature of the research environment and IQVIA’s pivotal role within it. With North America accounting for more than 33% of , propelled by supportive regulations and governmental assistance, IQVIA, one of the biggest , plays a key role in this expansion, supported by its dedication to quality and adherence.

Moreover, the influence of our research efforts reaches local economies, promoting job creation, healthcare enhancement, and international cooperation. As Marlene Greenfield, Vice President at Hearst Magazines, aptly puts it,

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation,

highlighting the importance of accessible data in the industry.

Furthermore, the success of one of the biggest , IQVIA, is reflected in a notable , projected to reach 2-5% through 2028, driven by heightened patient engagement and the adoption of high-value therapies. The insights from the case examination titled ‘Geographical Market Analysis’ further highlight that the area’s current infrastructure and governmental assistance greatly aid in the expansion of medical investigations and the software market for healthcare experiments, emphasizing IQVIA’s essential role in influencing the future of medical exploration.

4. Parexel: Innovating Clinical Development Solutions

Parexel stands out in the research landscape for its designed to enhance the research process. With the market size expected to reach USD 84.7 billion in 2024, Parexel’s extensive array of services—including feasibility studies, site selection, compliance reviews, setup, import permits, project management, and , inventory, and adverse events—prioritizes and . This emphasis has established the organization as a leader in the industry, setting new benchmarks for excellence in care.

Recent advancements in study management highlight Parexel’s dedication to utilizing technology and data analytics, which not only enhance study efficiency but also speed up the introduction of new therapies to market. For example, Parexel’s innovative solutions have been crucial in and optimizing study outcomes. In 2024, these strategies are anticipated to transform development metrics, with Parexel spearheading the movement towards more effective and patient-centered studies.

Experts within Parexel affirm that by adopting such approaches, the industry can foster a more collaborative environment, ultimately benefiting both patients and stakeholders alike. Additionally, as noted by Florence Mowlem, PhD, Vice President of Science for ObvioHealth:

• “I hope this can be a turning point for the industry with regard to comparability testing. We can stop having [comparability] conversations so frequently, and instead we can start talking about optimizing our electronic measures for all individuals.”

Furthermore, PSI, a fast-growing CRO specializing in oncology, hematology, and infectious diseases, has demonstrated success in the industry, receiving , and Reliability for the sixth consecutive year. This highlights the competitive landscape in which Parexel operates, as it is recognized among the biggest contract research organizations, and underscores its commitment to excellence, particularly in through international collaboration and innovation in medtech.

5. PRA Health Sciences: A Comprehensive Approach to Research

PRA Health Sciences distinguishes itself in the field of medical studies for its comprehensive approach, offering a wide range of services that cover every aspect of trials. Their offerings range from meticulous study design and efficient patient recruitment to comprehensive data management and stringent regulatory compliance. This comprehensive assistance is crucial for clients maneuvering through the intricacies of medical studies.

Pra’s unwavering dedication to quality and has established them as a trusted ally for pharmaceutical and biotech firms. Notably, industry leaders emphasize that in the (CROs) is critical for driving successful project outcomes. As one industry leader stated,

‘There is only one boss.

The customer. And he can fire everybody in the company from the chairman on down, simply by spending his money somewhere else.’

Furthermore, Pra’s commitment to fostering innovation and collaboration not only enhances their operational efficiency but also significantly contributes to delivering positive results for clients and improving .

In Latin America, bioaccess™ has risen as a prominent , particularly partnering with Caribbean Health Group to establish Barranquilla as a top location for studies, backed by ‘s Minister of Health. Their partnership with has yielded remarkable results, achieving and an impressive 95% retention rate. Input from customers consistently highlights Pra’s efficiency, showcasing their skill in overseeing successful studies and attaining significant progress in medical science.

As the industry evolves, with for their call centers and , Pra’s integration of cutting-edge technologies into their services positions them at the forefront of the industry. Additionally, users can manage their cookie preferences at any time to enhance their website experience, ensuring compliance and transparency in their interactions.

6. ICON plc: Global Expertise in Clinical Trials

As one of the biggest (CROs), ICON plc boasts extensive expertise in managing across various therapeutic areas. Their extensive service capabilities encompass:

• Feasibility and selection of research locations
• Principal investigator (PI) selection
• Compliance reviews of research documents
• Setup
• Import permits
• Nationalization of investigational devices
• Ethics committee approvals

With a global footprint spanning over 40 countries, ICON, recognized as one of the biggest , provides clients invaluable access to and , driving efficient trial execution and .

This strategic positioning is further solidified by their commitment to on study status, including serious and non-serious adverse events. In light of industry growth, as shown by Medpace’s plans to create 1,500 jobs and invest $150 million in expansion, ICON, recognized as one of the biggest , continues to demonstrate its in medical studies. Their and are crucial in fostering study success, contributing not only to healthcare improvement but also to job creation and economic growth in local economies.

As they revise their research studies for 2024, ICON demonstrates a commitment to remaining at the forefront in the evolving field of medical research, highlighting their capacity to adjust and succeed in a competitive market. This aligns with the industry’s sentiment that growth and innovation are essential for the advancement of medical science and improving patient care.

7. Syneos Health: Bridging the Gap Between Development and Commercialization

Syneos Health distinguishes itself in the industry due to its integrated model that effectively connects development and commercialization. Their comprehensive service capabilities encompass:

• Feasibility analysis
• Site selection
• Compliance reviews
• Trial setup
• Import permits
• Project management
• Reporting
• Review and feedback on documents to adhere to country requirements

This empowers clients to navigate the complexities associated with bringing innovative therapies to market.

By seamlessly merging healthcare and commercial services, Syneos Health improves patient engagement, which is essential for the overall success rates of new product launches. The 2023 landscape saw 24 , underscoring the importance of robust . As Murray Aitken noted, ‘The composite to 10.8% across after falling to a 10-year low in 2022, driven by increases in Phase I, Phase III and regulatory success.’

This statistic highlights the improving industry performance, which Syneos Health is well-positioned to leverage. Furthermore, their emphasis on and innovation in corresponds with the wider influence of on local economies, including job creation, economic growth, and healthcare improvement. Syneos Health’s services contribute to these outcomes by fostering local partnerships and supporting workforce development initiatives.

The case study of HCG illustrates how Syneos Health’s integrated approach accelerates the impact of on real-world healthcare, emphasizing the importance of streaming campaigns for pharma brands to enhance awareness and sales. Syneos Health leaders stress that relies on collaboration and innovation, further reinforcing the organization’s position as a crucial ally for companies seeking to enhance both development and commercialization efforts. Their proactive approach not only fosters a successful trajectory for their clients but also aligns with the industry’s evolving demands.

8. Labcorp Drug Development: Comprehensive Drug Development Services

Labcorp Drug Development stands out as one of the biggest , recognized for its extensive range of that include preclinical research, , and laboratory services. Their expertise in site feasibility and investigator selection ensures that studies are conducted efficiently and in compliance with regulatory requirements. Additionally, Labcorp excels in study set-up, start-up, and obtaining necessary approvals from ethics committees and health ministries, which are critical for advancing medical device studies.

This extensive array of capabilities empowers clients to effectively streamline their drug development processes, significantly reducing time to market. Recent advancements within Labcorp have been crucial; for instance, the company’s research management services have been improved, reflecting their commitment to operational excellence and . As noted by Leslie Rivera Rosado, a supervisory interdisciplinary scientist at the FDA, ‘The FDA has observed a rise in complete response letters (CRLs) issued to sponsors of biologics license applications (BLAs) over the last decade, with facility deficiencies being the most common reason cited.’

This highlights the critical importance of in Labcorp’s operations. Furthermore, in relation to Colombia’s competitive advantages, Labcorp, one of the biggest , utilizes cost efficiency, regulatory speed, and high-quality healthcare, positioning itself advantageously for . By harnessing their global network and deep expertise, Labcorp not only supports clients in advancing their drug development programs but also aims to enhance patient outcomes.

Their project management and monitoring processes ensure that study status and inventory are meticulously reported, including serious and non-serious . Their 2023 Corporate Responsibility Report explicitly details their commitment to corporate responsibility, showcasing initiatives in governance, diversity, and environmental sustainability that align with their corporate values. Through these efforts, Labcorp continues to play a transformative role in the pharmaceutical landscape, driving innovation and success in research studies.

9. Charles River Laboratories: Advancing Drug Discovery and Development

Charles River Laboratories is a leader among the biggest , specializing in the essential area of drug discovery and development. Their extensive encompass:

• Feasibility assessments
• Selection of trial sites and lead investigators
• Compliance evaluations of documentation to fulfill country requirements
• Trial setup
• Import permits
• Project management
• Reporting on

This robust suite of services is designed to support the in making informed decisions during the early stages of drug development.

A notable example of their impact is seen in AstraZeneca’s , which underscores the significance of Charles River’s services in advancing drug development. Through their innovative methodologies and international collaborations, Charles River empowers clients to optimize strategies and enhance the likelihood of successful outcomes, driving global health improvement in the Medtech sector. As Charlie Sternberg notes, ‘The lab in California is fully operational and has already released ,’ reflecting their commitment to excellence and innovation.

Recent statistics indicate a marked increase in success rates for , one of the biggest , providing further evidence of their pivotal role in the industry. Moreover, significant collaborations, like the one with AdvanCell and Lilly, demonstrate how they utilize advanced production technologies and drug candidate programs, improving their clients’ capabilities and strengthening their reputation as a reliable partner in advancing globally.

10. Medpace: A Full-Service Clinical Research Organization

Medpace distinguishes itself as one of the biggest by providing a broad range of services aimed at supporting every stage of . Their expertise ranges from feasibility studies and site selection to experiment setup, project management, compliance reviews, data analysis, and regulatory submissions, enabling them to offer clients throughout the research process. Medpace places a strong emphasis on operational excellence, which is reflected in their efficient study execution and commitment to quality and patient safety.

This commitment is especially pertinent in the context of , which have gained traction due to the COVID-19 pandemic. As emphasized in a recent case analysis, decentralized trials can enable , increase , and help research achieve recruitment goals, especially for the 70% of the population living far from academic medical centers. Medpace’s underscore the effectiveness of their methodologies, allowing for significant improvements in recruitment rates.

Furthermore, the economic impacts of are notable, contributing to in local economies. As Dave Marver, CEO of ONWARD Medical, mentioned at the 23rd Annual Needham Virtual Healthcare Conference, ‘This makes us the FIRST company in the world to receive breakthrough designation for a BCI paired with therapeutic stimulation,’ highlighting the significance of innovation and quality in medical studies. Medpace’s establishes them among the biggest , making them an invaluable partner for organizations aiming to advance their clinical research initiatives while maintaining the highest standards of excellence.

Conclusion

The vital role of Contract Research Organizations (CROs) in the realm of clinical research cannot be overstated. These organizations are instrumental in facilitating the efficient progression of innovative therapies from concept to market, ensuring that clinical trials are conducted with the utmost quality and compliance. By leveraging their extensive expertise in areas such as:

• Site feasibility
• Patient recruitment
• Regulatory submissions
• Data management

CROs not only help streamline the research process but also significantly enhance patient outcomes.

As highlighted in this article, several top-tier CROs, including IQVIA, Parexel, and Medpace, exemplify the standards of excellence that drive the industry forward. Their commitment to innovation, patient-centric approaches, and operational excellence underscores their importance in navigating the complexities of clinical trials. The competitive advantages offered by regions like Colombia further illustrate the global landscape of clinical research, showcasing how local collaboration and government support can create optimal environments for conducting first-in-human trials.

Ultimately, the continued evolution and adaptation of CROs to meet the demands of a rapidly changing healthcare environment are crucial for advancing medical science. As these organizations enhance their capabilities and expand their reach, they will play an increasingly pivotal role in bringing life-saving therapies to patients around the world. The future of clinical research is bright, and CROs stand at the forefront, ready to lead the charge in delivering impactful healthcare solutions.

Frequently Asked Questions

What role do contract research organizations (CROs) play in the pharmaceutical and biotechnology industries?

CROs act as essential collaborators by providing specialized outsourced services that include site feasibility, investigator selection, study set-up, start-up approvals, regulatory compliance, project management, and monitoring, which ensures adherence to regulatory standards and facilitates the development of innovative therapies.

What specific services do CROs offer?

CROs provide a variety of services, including study design, patient recruitment, data management, regulatory submissions, and ongoing monitoring, all of which are vital for the successful execution of research projects.

What advantages does Colombia offer for first-in-human studies?

Colombia offers competitive benefits such as cost efficiency, regulatory speed, high-quality healthcare, effective patient recruitment, and R&D tax incentives, making it an attractive location for medical trials.

How is Barranquilla positioned in the context of clinical studies in Latin America?

Barranquilla is being positioned as a leading destination for medical trials in Latin America through collaboration between bioaccess™ and Caribbean Health Group, supported by Colombia’s Minister of Health, highlighting governmental dedication to enhancing its appeal for clinical studies.

How do CROs help sponsors in the research process?

By leveraging the expertise of CROs, sponsors can focus on their core competencies while benefiting from enhanced efficiency and reduced costs throughout the study process.

What recognition has PSI received in the CRO industry?

PSI has been recognized with the CRO Leadership Awards for Expertise, Quality, and Reliability for six consecutive years, underscoring its commitment to excellence in the industry.

What factors determine the ranking of the biggest CROs?

The ranking is based on revenue performance, market share, global reach, client satisfaction, and the effectiveness of service offerings, particularly in comprehensive trial management services.

What specific services are included in comprehensive trial management by CROs?

Services include feasibility studies, site selection, compliance reviews, trial setup, import permits, project management, and reporting.

How does adaptability to industry demands affect CRO rankings?

Adaptability ensures that CROs not only lead in size but also significantly contribute to advancing clinical studies, enhancing patient outcomes, and positively impacting local economies.

What is IQVIA’s role as a CRO?

IQVIA utilizes data analysis and advanced technology to provide thorough solutions, including feasibility assessments, site selection, compliance reviews, trial setup, and project management, supporting all phases of medical development.

How does IQVIA contribute to the healthcare market?

IQVIA plays a key role in the expansion of the research software market and medical investigations, supported by its dedication to quality and adherence to regulations, promoting job creation and healthcare enhancement.

What is the projected growth for the U.S. market in the CRO sector?

The U.S. market is projected to experience a CAGR increase of 2-5% through 2028, driven by heightened patient engagement and the adoption of high-value therapies.

List of Sources

1. 1. Understanding Contract Research Organizations (CROs): An Overview
   • biomedstat.com (https://biomedstat.com/news-1/the-biggest-10-clinical-research-organizations-cros-shaping-global-healthcarenbsp)
   • lindushealth.com (https://lindushealth.com/blog/top-20-cros-in-2024-a-comprehensive-ranking)
   • proclinical.com (https://proclinical.com/blogs/2024-5/top-10-cros-to-watch-in-2024)
   • precisionformedicine.com (https://precisionformedicine.com/blog/top-oncology-cros-in-2024-and-beyond)
2. 2. Criteria for Ranking the Top Contract Research Organizations
   • tfscro.com (https://tfscro.com/resources/top-10-contract-research-organizations-cros-in-2024)
   • proclinical.com (https://proclinical.com/blogs/2024-5/top-10-cros-to-watch-in-2024)
   • Contract Research Organizations in the US Industry Analysis, 2025 (https://ibisworld.com/united-states/industry/contract-research-organizations/5708)
3. 3. IQVIA: Leading the Charge in Clinical Research
   • Global Trends in R&D 2024: Activity, productivity, and enablers (https://iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers)
   • statista.com (https://statista.com/statistics/859628/revenue-streams-iqvia-by-operation)
   • globenewswire.com (https://globenewswire.com/news-release/2025/01/02/3003462/0/en/Clinical-Trials-Software-Market-Report-2024-2029-Key-Trends-Include-Reduction-in-Trials-Expenses-with-Clinical-Trials-Software-Enhancing-Data-Privacy-and-Security-Rapid-Clinical-Tr.html)
   • The Global Use of Medicines 2024: Outlook to 2028 (https://iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028)
4. 4. Parexel: Innovating Clinical Development Solutions
   • Clinical Trials Market Size And Share | Industry Report, 2033 (https://grandviewresearch.com/industry-analysis/global-clinical-trials-market)
   • Clinical Trial Insight and Trends For 2024 And Beyond (https://obviohealth.com/resources/clinical-trial-trends-2024)
   • proclinical.com (https://proclinical.com/blogs/2024-5/top-10-cros-to-watch-in-2024)
5. 5. PRA Health Sciences: A Comprehensive Approach to Research
   • marketbeat.com (https://marketbeat.com/stocks/NASDAQ/PRAH)
   • 59 AI customer service statistics for 2026 (https://zendesk.com/blog/ai-customer-service-statistics)
   • 135+ Customer Service Statistics You Need to Know in 2026 | AmplifAI (https://amplifai.com/blog/customer-service-statistics)
6. 6. ICON plc: Global Expertise in Clinical Trials
   • proclinical.com (https://proclinical.com/blogs/2024-5/top-10-cros-to-watch-in-2024)
   • pharmiweb.com (https://pharmiweb.com/press-release/2024-05-20/clinical-trial-imaging-market-set-for-exceptional-growth-78-cagr-expected-marketus)
7. 7. Syneos Health: Bridging the Gap Between Development and Commercialization
   • mmm-online.com (https://mmm-online.com/home/channel/both-syneos-health-and-fsd-pharma-claim-wins-in-fight-over-trial-recruiting)
   • syneoshealth.com (https://syneoshealth.com/solutions/clinical-development/phase-ii-iv/biostatistics-and-statistical-programming)
   • Global Trends in R&D 2024: Activity, productivity, and enablers (https://iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers)
8. 8. Labcorp Drug Development: Comprehensive Drug Development Services
   • linkedin.com (https://linkedin.com/in/heidin-nielsen)
   • forbes.com (https://forbes.com/companies/labcorp)
   • ir.labcorp.com (https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-2024-first-quarter-results)
9. 9. Charles River Laboratories: Advancing Drug Discovery and Development
   • contractpharma.com (https://contractpharma.com/breaking-news/charles-river-sanofi-partner-to-reduce-the-use-of-animals-in-research)
   • patholytix.com (https://patholytix.com/news-and-events/charles-river-and-deciphex-launch-patholytix-foresight-a-transformative-ai-powered-decision-support-tool-for-toxicologic-pathology)
   • fiercebiotech.com (https://fiercebiotech.com/research/conduit-taps-charles-river-build-preclinical-autoimmune-case-astrazeneca-diabetes-asset)
10. 10. Medpace: A Full-Service Clinical Research Organization

• linkedin.com (https://linkedin.com/posts/medpace_we-are-thrilled-to-announce-that-medpace-activity-7216831108871569408-K1Ss)
• antidote.me (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)

Introduction

Understanding the complexities of packaging testing in Argentina is crucial for businesses that want to comply with local regulations and ensure consumer safety. This guide offers a thorough overview of the essential steps for selecting the right laboratory for packaging testing. It highlights key factors such as accreditation, specialization, and sample preparation. However, with a landscape filled with various testing requirements and standards, companies must ask: how can they navigate these challenges to ensure their products not only meet compliance but also thrive in a competitive market?

Understand Packaging Testing Requirements in Argentina

Before diving into order in the , it’s essential to grasp the specific requirements set forth by Argentine regulations. Understanding these regulations is not just a formality; it’s a critical step in and . Familiarizing yourself with the your packaging may need to undergo is paramount:

• Mechanical Testing: This evaluates the physical durability of packaging materials under various conditions, ensuring they can withstand handling and transportation.
• Chemical Testing: This ensures that container materials do not leach harmful substances into the products they hold, .
• Microbiological Testing: This ensures that containers are free from harmful microorganisms, which is particularly critical for food and pharmaceutical products.

In addition to these tests, awareness of the , the , and is crucial. Adhering to these regulations is vital for acquiring the necessary , ensuring that your products meet local legal standards. Notably, products that comply with regulations must display the on their containers. Furthermore, the container must include the name, country of origin, quality, purity or blend, and net weight of contents, as stipulated by local regulations. According to PIAnalysis Company, the Argentina Market is projected to reach USD 0.06 billion in 2022, underscoring the importance of compliance in a rapidly growing market.

Select an Accredited Laboratory for Testing

When selecting an , it’s crucial to follow a to ensure you make the best choice for your needs.

1. : Start by confirming that the facility holds certifications from recognized organizations, such as . This accreditation signifies adherence to international assessment standards, which is essential for reliable testing.
2. Assess Proficiency: Look for laboratories that specialize in testing relevant to your sector – be it food, pharmaceuticals, or consumer products. This focus ensures that the lab understands the .
3. : Investigate the facility’s reputation by reading reviews and testimonials from previous clients. A can provide confidence in the lab’s capabilities.
4. Assess Capabilities: Ensure that the is equipped with the to conduct the specific tests required for your packaging. This step is vital for obtaining accurate results.
5. Request Quotes: Finally, . Comparing pricing and services will help you make an informed decision that aligns with your budget and expectations.

By following these steps, you can confidently choose a facility that delivers precise and dependable results.

Prepare and Submit Samples for Testing

To ensure successful testing of your packaging samples in , it’s crucial to follow these :

1. Understand : Familiarize yourself with the laboratory’s guidelines regarding sample size, type, and specific preparation instructions. This knowledge is vital, as non-compliance can lead to delays or certification refusals.
2. : Each sample must be labeled with pertinent information, including the product name, batch number, and specific testing requirements. Proper labeling is essential; in fact, 76% of consumers show increased loyalty to brands that provide .
3. Package Samples Properly: Utilize appropriate materials to safeguard samples during transport. Ensure they are securely sealed and cushioned to prevent damage. in the lab not only protects the samples but also aligns with best practices that can enhance customer satisfaction and reduce costs.
4. : Accurately fill out all necessary forms and paperwork mandated by the facility, detailing the samples and the tests requested. Insufficient or non-compliant documentation can lead to sample rejection, emphasizing the importance of thorough preparation.
5. : Send the samples to the as soon as they are ready to prevent degradation or contamination. Timely shipping is essential, as delays can lead to and certification refusals.

By following these steps, you can ensure a smooth testing process and achieve dependable outcomes, ultimately improving your product’s market readiness.

Interpret Test Results and Plan Next Steps

Upon obtaining the from the lab, it is essential to to guarantee conformity and preparedness for . Follow these steps:

1. Examine the Report Carefully: Analyze all parts of the report, including test methods, findings, and any notes or comments from the laboratory. This comprehensive review is essential for understanding the context of the findings.
2. Identify Key Findings: Concentrate on that demonstrate if your containers satisfy the necessary standards. Look for pass/fail indicators and any areas of concern, as these will guide your next steps.
3. : Engage with your team or external specialists to discuss the findings. Their insights can clarify technical aspects and help address any uncertainties regarding compliance or performance. As Lisa McTigue Pierce, Executive Editor of Packaging Digest, highlights, “Comprehending the subtleties of is crucial for ensuring that containers conform to both and market expectations.”
4. : Based on the findings, evaluate whether changes to your containers are necessary. This may involve redesigning materials or adjusting manufacturing processes to enhance compliance and performance. Remember, as highlighted in recent studies, establishing production process capability before starting production is crucial to mitigate risks and ensure a smooth product launch.
5. : Maintain detailed records of any adjustments made in response to the . This documentation is vital for future regulatory submissions and demonstrates your commitment to quality and compliance. Maintaining comprehensive documentation also helps in complying with industry standards established by entities such as ASTM International, ISTA, and ISO, which are crucial for guaranteeing dependable and comparable outcomes in testing.

By effectively interpreting test results, you can ensure that your packaging not only meets but also aligns with market expectations, ultimately facilitating a smoother entry into the competitive landscape.

Conclusion

Navigating the complexities of order packaging testing in Argentina is essential for businesses that want to ensure compliance with local regulations and protect consumer health. This systematic approach not only clarifies the requirements but also guides organizations in selecting an accredited laboratory, preparing samples correctly, and interpreting test results effectively. By adhering to these steps, companies can significantly enhance their product readiness and meet the necessary standards for market entry.

Key insights highlight the critical role of:

• Mechanical testing
• Chemical testing
• Microbiological testing

in verifying the safety and durability of packaging materials. Moreover, choosing a laboratory with the appropriate accreditations and expertise is vital for obtaining reliable results. Proper sample preparation and timely submission streamline the testing process, while a thorough analysis of test findings ensures that any necessary adjustments are made to comply with regulatory standards.

Ultimately, the importance of order packaging testing in Argentina cannot be overstated. It not only fosters compliance with local laws but also builds consumer trust and satisfaction. Businesses are strongly encouraged to prioritize these testing procedures as part of their product development strategy, ensuring they are well-prepared to navigate the competitive landscape and respond to evolving market demands.

Frequently Asked Questions

What are the main types of packaging tests required in Argentina?

The main types of packaging tests required in Argentina are Mechanical Testing, Chemical Testing, and Microbiological Testing.

What does Mechanical Testing evaluate?

Mechanical Testing evaluates the physical durability of packaging materials under various conditions to ensure they can withstand handling and transportation.

Why is Chemical Testing important for packaging?

Chemical Testing is important because it ensures that container materials do not leach harmful substances into the products they hold, thereby safeguarding consumer health.

What is the purpose of Microbiological Testing?

Microbiological Testing ensures that containers are free from harmful microorganisms, which is particularly critical for food and pharmaceutical products.

Which organizations set the relevant standards for packaging testing in Argentina?

The relevant standards for packaging testing in Argentina are established by the Argentine Food Code and the National Administration of Drugs, Food and Medical Technology (ANMAT).

What must products display to comply with Argentine regulations?

Products that comply with regulations must display the official safety mark ‘S’ on their containers.

What information must be included on the packaging according to local regulations?

The packaging must include the name, country of origin, quality, purity or blend, and net weight of contents, as stipulated by local regulations.

What is the projected size of the Argentina Packaging Testing Market?

The Argentina Packaging Testing Market is projected to reach USD 0.06 billion in 2022.

List of Sources

1. Understand Packaging Testing Requirements in Argentina
   • Packaging and standards – Packaging and standards – Santandertrade.com (https://santandertrade.com/en/portal/analyse-markets/argentina/packaging-and-standards)
   • Argentina Packaging Testing Market Size, Trends & Forecast Analysis (2025-2033) (https://packagingmarketinsights.com/vision/insights/packaging-testing-market/argentina)
   • Argentina Overhauls Rules for Cosmetics and Hygiene Products (https://gpcgateway.com/news/detail/argentina-overhauls-rules-for-cosmetics-and-hygiene-products/MjE5MQ)
   • Argentina Pharmaceuticals Packaging Testing Equipment Market Size, Share & Growth Analysis By [2033] (https://packagingmarketinsights.com/vision/insights/pharmaceuticals-packaging-testing-equipment-market/argentina)
   • Top Content on LinkedIn (https://linkedin.com/pulse/argentina-product-packaging-testing-market-size-5ylie)
2. Select an Accredited Laboratory for Testing
   • Argentina Packaging Testing Market Size, Trends & Forecast Analysis (2025-2033) (https://packagingmarketinsights.com/vision/insights/packaging-testing-market/argentina)
   • LA Package Testing Market Size | Mordor Intelligence (https://mordorintelligence.com/industry-reports/latin-america-package-testing-market-industry)
   • Choosing the Right Laboratory for International Testing: A Practical Guide – «WorldWideBridge» (https://wwbridge-cert.com/blog/posts/choosing-the-right-laboratory-for-international-testing-a-practical-guide)
   • Moving Latin American Laboratories Forward by Giving Back (https://myadlm.org/science-and-research/journal-of-applied-laboratory-medicine/jalm-talk/2016/moving-latin-american-laboratories-forward-by-giving-back)
   • Packaging Testing (https://sgs.com/en-ar/service-groups/packaging-testing)
3. Prepare and Submit Samples for Testing
   • 8 Surprising Stats about Packaging You Need to Know (https://medium.com/packmojo/8-surprising-stats-about-packaging-you-need-to-know-622d57faaaa3)
   • 50+ Ecommerce packaging statistics for smarter brands | Woola (https://woola.io/blog/ecommerce-packaging-statistics)
   • How to Properly Prepare Samples for Testing – «WorldWideBridge» (https://wwbridge-cert.com/blog/posts/how-to-properly-prepare-samples-for-testing)
   • Ecommerce Packaging | Statistics About Packaging (https://meteorspace.com/2025/01/15/important-statistics-about-packaging-you-need-to-know)
   • 25 Key Packaging Statistics You Should Know in 2025 (https://uprinting.com/blog/packaging-statistics?srsltid=AfmBOopja6RmUuAtfeq_mBuH2uAY5ek9mXllViPwbSERss0_ZIOXIg4X)
4. Interpret Test Results and Plan Next Steps
   • Master Packaging Testing for Better Products (https://peekage.com/blog/packaging-testing)
   • Words of wisdom from your packaging peers: Gallery (https://packagingdigest.com/careers-education-training/words-of-wisdom-from-your-packaging-peers-gallery)
   • Application of statistical techniques in the evaluation of packaging processes (https://repository.rit.edu/theses/173)
   • Is Statistical Analysis Required in Packaging? | Packaging Compliance Labs (https://pkgcompliance.com/is-statistical-analysis-required-in-packaging)
   • Performance Testing for Combination Product & Drug Packaging (https://westpharma.com/blog/2025/february/performance-testing-drug-packaging-combination-products?srsltid=AfmBOoo57P005pNNW7ZkdxxfECovVXSEx6JUE_UdT1QmN6GbDiPCl-7X)

Introduction

Clinical trials play a crucial role in evaluating the effectiveness of new treatments and interventions. Central to these trials are the primary endpoints, which serve as the key outcomes that the study aims to assess. The selection of these endpoints is not only essential for the success of the trial but also for the validity and reliability of its findings.

In this article, we will explore the importance of endpoint selection in clinical trials, the characteristics of effective endpoints, the different types of endpoints, commonly used endpoints, the challenges in selecting primary endpoints, statistical considerations in endpoint selection, and a case study highlighting successful endpoint selection in practice. By understanding the intricacies of endpoint selection, we can enhance our understanding of clinical trials and contribute to the advancement of medical research and patient care.

Importance of Endpoint Selection in Clinical Trials

Within the domain of , the identification of is a crucial determination that affects the integrity of the study and its findings regarding the novel therapies or interventions being examined. These serve as the central outcomes that the study is set up to assess. Their careful selection is not only a marker of a trial’s success but also a safeguard for the validity and reliability of its findings. To address the complexities of such a selection, a stepwise process has been formulated. This includes defining a causal question, choosing appropriate information, evaluating precision, planning robustness assessments, and conducting inferential analyses. The process underscores the importance of avoiding bias, especially in that hinge on real-world healthcare data. Tools like ROBINS-I and GRACE checklist aid in , while RECORD-PE and Start-RWE enhance transparency in reporting. Similarly, the HARPER protocol template fosters clear communication of study parameters and is endorsed by regulators for non-interventional study designs. These measures are essential in improving the of experiments, thus strengthening the evidence generated for .

Characteristics of Effective Endpoints

When it comes to , the choice of main and additional outcomes is a decision of utmost significance. These termination points must not only align with the scientific goals of the research but also need to be measurable and responsive enough to identify the effects of the intervention under examination. Aligning endpoints with the goals of the trial also requires a profound understanding of the information and methodologies at hand. and Thompson Sampling (TS) are two of the methods used to assign treatments to patients, with ER being straightforward and TS aligning the likelihood of receiving a treatment with its potency. Furthermore, the integration of insights from various digital sources, such as connected devices and electronic diaries, has emphasized the value of . This extensive range of information sources requires a to guarantee the integrity and quality of the collected information. Ensuring that endpoints are , measurable, and interpretable is not a task taken lightly, as it involves meticulous planning and expert knowledge to anticipate and address potential issues in data management and oversight. The challenges emphasized by the World Health Organization, from inadequate experiment design to restricted participant diversity, highlight the continuous need for improvement in the field. With less than 5% of experiments involving pregnant women and only 13% including children, there is an apparent gap in inclusivity that must be addressed. must aim to be cost-effective, provide the best treatment to as many as possible, and be likely to yield accurate results. Balancing these aims is a delicate act, but one that is essential for the advancement of medical research and the betterment of public health worldwide.

Types of Endpoints: Direct, Surrogate, and Composite

In , comprehending the range of terminations is vital for propelling advancements in . Primary results are the most significant consequences that closely match the research question or goal, offering a clear response to the study’s hypothesis. Secondary results, although not the primary emphasis, provide corroborating evidence and may encompass supplementary perspectives such as . are particularly beneficial as they amalgamate multiple single outcomes into a more comprehensive measure, allowing for a broader assessment of treatment effects.

For example, Pfizer’s clinical trial for the potential cachexia treatment, ponsegromab, demonstrates the utilization of composite outcomes. Patients with cachexia, a severe wasting condition in cancer, saw improvements in body weight, muscle mass, quality of life, and physical function. This holistic view, afforded by composite endpoints, is essential for conditions like cachexia where multiple factors influence patient health.

However, clinicians and researchers must navigate the complexity of information interpretation, as healthcare providers often encounter intricate statistical information, such as survival curves and bar graphs. Research indicates that numerous healthcare practitioners face challenges with intricate information presentations, emphasizing the importance of clarity in showcasing . This is particularly relevant as set standards for quality and safety, emphasizing the importance of to improve patient outcomes.

Comprehending these various types of endpoints—and interpreting them accurately—is more than an academic exercise; it is a responsibility to the patients who stand to benefit from the advancements these studies bring about.

Commonly Used Endpoints in Clinical Trials

Endpoints in are crucial for assessing the efficacy of therapeutic interventions. They range from measuring and to response rates, quality of life, and the incidence of adverse events. These measures are chosen for their and their capacity to reflect the impact of the treatment under study. In cardiology, for example, (MACE) are used as a combined result to capture different cardiovascular consequences. In oncology trials, (PFS) and (DFS) are often used as substitutes for more conclusive measures such as overall survival or health-related quality of life.

The selection and reporting of endpoints require careful consideration. As mentioned in the management of multiple coronary lesions, where choices involve multiple stents versus coronary bypass surgery, the selected results must be consistently reported to provide clear insights into the effectiveness of interventions. In addition, it’s essential to maintain consistency in reporting outcomes over time for comparability.

may also utilize non-interventional studies, where treatments are not assigned according to a protocol but rather observed during routine medical practice. The FDA and EMA have differing definitions for these studies, highlighting the need for harmonization in regulations. For instance, the FDA does not require that there be no additional diagnostic or monitoring procedures, whereas the EMA does.

Furthermore, stakeholders such as Regeneron Pharmaceuticals have requested more explicit direction regarding non-interventional research, proposing the establishment of dependable information sources and verification methods to guarantee the quality of information. The National Organization for Rare Disorders (NORD) emphasized the importance of observational studies, especially for rare diseases, and advocated for more specific guidance.

Data quality and integrity are crucial in , as highlighted by issues encountered with paper-based patient-reported measures (Proms). Research has indicated that 44% of patients using paper diaries either missed or ambiguously marked items, causing concerns about the quality of information. Electronic information capture methods have been suggested to improve the accuracy and dependability of clinical outcome assessments and alleviate the challenges linked to paper-based collection.

In summary, the meticulous choice and consistent documentation of outcomes, together with the implementation of digital data collection techniques, are critical in enhancing the comprehension of and, ultimately, healthcare for patients.

Challenges in Selecting Primary Endpoints

The intricacies of choosing main objectives for are multifaceted, encompassing a combination of rigorous scientific approaches and practical logistics. One must consider the ability to measure the final outcome reliably within the trial’s timeline. The DAPA-MI study exemplifies this challenge. Initially, the primary endpoint was a composite of hospitalization for heart failure and cardiovascular death. However, the number of primary composite outcomes accrued was lower than anticipated, prompting reevaluation. The incorporation of with randomized experiment components in this study, a registry-based randomized controlled investigation (R-RCT), aimed to reconcile the need for reliable data with the practicalities of patient enrollment and cost considerations.

In oncology, the growing use of reflects an understanding that survival metrics alone do not fully capture treatment impacts. Instruments like the NSCLC-SAQ for non-small cell lung cancer are increasingly employed to gauge multiple symptom dimensions, addressing the sometimes insufficiently quantitative survival endpoints.

Conversations among specialists, including those from health technology and regulatory agencies, highlight a modular approach to PRO administration in interventional experiments. This approach, while not addressing how subscales are selected, which is crucial, does focus on the methodological and statistical justification for modular implementation, aiming to enhance patient-centric drug development.

Globally, the difference in between high-income and low- and middle-income countries demonstrates the need for more equitable research practices. ‘WHO’s recommendations and the FDA’s commitment to harmonizing human subject protection regulations exemplify efforts to enhance experiment design and participant diversity.’.

Statistical considerations are equally paramount. Frequentist and Bayesian methodologies offer contrasting approaches to design and analysis, with the latter recommended for its flexibility in a dynamic research environment. The SPIRIT-Surrogate extension provides guidelines for reporting protocols using substitute goals, underscoring the importance of transparent and replicable methods for reliable conclusions.

are essential for medical progress but encounter obstacles such as delays and high rates of failure to finish on schedule. With the average duration of Phase 3 trials increasing and the pressures of the Inflation Reduction Act, the necessity to optimize has never been more crucial. As pointed out by McKinsey, the gathering in biopharma intensifies the race to be the first to market, emphasizing the significance of efficient conduct. , which compare the effectiveness of a new treatment to an existing one, demonstrate the delicate balance between showing effectiveness and emphasizing additional advantages that could outweigh the risks. Transparency in objectives is essential to ensuring that new treatments with potential benefits are not overlooked simply because they do not meet conventional non-inferiority margins.

Statistical Considerations in Endpoint Selection

Choosing the most suitable outcome measures in clinical studies is a procedure emphasized by thorough . Sample sizes are not arbitrary numbers; they are meticulously calculated to ensure that the study has adequate power to detect a significant effect of the treatment under investigation. The main goal, specifically, is a crucial factor of a study’s statistical power, impacting the feasibility and significance of the experiment’s results.

To contextualize this, consider a cross-over study design used in . Each participant receives both the test and reference drug in successive periods, allowing researchers to observe differences in pharmacokinetic responses. Through statistical models, such as the calculation of the geometric mean ratio from log-transformed information, we can infer bioequivalence between the two treatments.

have become increasingly relevant, providing a flexible approach to integrating prior data with current research, thus enhancing the decision-making process. This methodology has gained traction in regulatory submissions, offering valuable insights that traditional frequentist methods may not provide, especially in complex trial designs.

However, it’s not just about choosing the right statistical tools; it’s also about understanding what the numbers truly represent. , for example, do not give us probabilities but rather allow us to estimate what might occur across a broader population based on our sample. This is akin to predicting election results based on a poll, where the margin of error gives us a range of potential outcomes, not a definitive answer.

In the spirit of continual advancement, the field of biostatistics celebrates its progress with discussions reflecting on the seminal work of Sir Austin Bradford Hill and the evolving role of statisticians in medicine. With 40 years of advancements, experts like Dr. Albert from the National Cancer Institute contribute to the development of that underpin the interpretation of .

The importance of robust statistical methods extends beyond the confines of high-income countries; it’s a global imperative to ensure equitable access to safe and effective health interventions. According to the World Health Organization, enhancing research and incorporating into regular services can close the gap between countries, ultimately improving global health.

Case Study: Successful Endpoint Selection in Practice

The choice of key outcomes in is a crucial element in assessing novel therapies. Consider a recent study targeting a specific cancer type. The researchers designated as the main focus, highlighting its importance in clinical relevance and expecting the new drug to surpass standard treatments in this critical aspect. Their results showed a marked improvement in , subsequently leading to of the new medication. These results emphasize the strategic significance of selecting the most appropriate to assess the effectiveness of a treatment in .

In the context of , it is important to acknowledge that while are the most vital focus, additional results also contribute to understanding the main result’s significance. A thorough comprehension of these results is crucial for researchers to communicate the importance of their findings efficiently and guarantee that their work tackles the intended research question or study aim. Moreover, the evolving landscape of trial reporting underscores the importance of transparently presenting all measured outcomes, as demonstrated by the modernized ClinicalTrials. Gov website, which now enhances the visibility of study records and their associated data elements.

Conclusion

In conclusion, the selection of primary endpoints in clinical trials is crucial for the validity and reliability of the study’s findings. It involves a stepwise process that includes defining a causal question, choosing appropriate data, evaluating precision, planning robustness assessments, and conducting inferential analyses. Effective endpoints must be scientifically relevant, quantifiable, sensitive enough to detect treatment impacts, and align with the goals of the trial.

Commonly used endpoints include overall survival, progression-free survival, response rates, quality of life, and adverse events.

However, challenges arise in selecting primary endpoints, such as limited participant diversity, statistical considerations, and the need for more equitable research practices. Statistical methods like Bayesian analysis play a vital role in endpoint selection. Ensuring clarity in presenting clinical trial outcomes is crucial for improving patient care.

A successful case study exemplifies the strategic importance of choosing relevant primary endpoints. The selection of overall survival as the primary endpoint led to marked improvements and subsequent regulatory approval of a new medication. Recognizing the role of secondary outcomes and transparently presenting all measured outcomes contribute to the understanding and significance of trial findings.

In summary, endpoint selection in clinical trials is a meticulous process that impacts the integrity and reliability of study findings. By understanding the complexities involved, we can enhance our understanding of clinical trials, improve trial design, and contribute to the advancement of medical research and patient care.

Learn more about the importance of selecting primary endpoints in clinical trials and how it impacts the validity and reliability of study findings.

Frequently Asked Questions

What are key outcomes in clinical research?

Key outcomes, or primary endpoints, are the main results that a clinical study aims to assess. They are crucial for determining the integrity and validity of the study’s findings regarding new therapies or interventions.

Why is the selection of key outcomes important?

The careful selection of key outcomes is essential as it serves as a marker for the trial’s success and safeguards the validity and reliability of its findings.

What process is used to select key outcomes?

A stepwise process is formulated to select key outcomes, which includes defining a causal question, choosing appropriate information, evaluating precision, planning robustness assessments, and conducting inferential analyses.

What tools assist in bias evaluation in clinical studies?

Tools such as ROBINS-I and the GRACE checklist help in evaluating biases, while RECORD-PE and Start-RWE enhance transparency in reporting. The HARPER protocol template also supports clear communication of study parameters.

How do primary and secondary outcomes differ?

Primary outcomes are the main focus of the study, providing a clear response to the research question. Secondary outcomes, while significant, provide additional corroborating evidence and may include subgroup analyses.

What are composite measures, and why are they useful?

Composite measures amalgamate multiple single outcomes into a broader assessment, allowing for a more comprehensive evaluation of treatment effects, especially in complex conditions like cachexia.

How is patient-centered drug development emphasized in clinical research?

The integration of insights from digital sources, such as connected devices and electronic diaries, highlights the importance of patient-centered approaches in drug development.

What are some challenges in endpoint selection and reporting?

Challenges include ensuring that endpoints are clinically relevant, measurable, and interpretable. There is also a need for consistency in reporting outcomes over time for comparability.

Why is participant diversity in clinical trials a concern?

Current research shows a lack of inclusivity, with few studies involving pregnant women or children. This gap highlights the need for more equitable research practices.

What statistical methods are used in clinical trials?

Frequentist and Bayesian methodologies are commonly used. Bayesian statistics allow for more flexibility in integrating prior data with current studies, enhancing decision-making.

How can data quality and integrity be improved in clinical trials?

Using electronic information capture methods can improve the accuracy and reliability of clinical outcome assessments, addressing issues encountered with paper-based measures.

What role do regulatory agencies play in clinical research?

Regulatory agencies, such as the FDA and EMA, provide guidelines and definitions for clinical trials, emphasizing the need for harmonization in regulations and supporting quality in non-interventional studies.

Why is it essential to understand and interpret various endpoints accurately?

Accurate interpretation of endpoints is crucial for ensuring that the findings of clinical studies are communicated effectively and that potential benefits for patients are fully realized.

List of Sources

1. Importance of Endpoint Selection in Clinical Trials
   • bmj.com (https://bmj.com/content/384/bmj-2023-076460?utm_campaign=usage&utm_content=tbmj_sprout&utm_id=BMJ005&utm_medium=social&utm_source=twitter)
   • first10em.com (https://first10em.com/how-to-create-a-focused-and-answerable-research-question)
   • infomeddnews.com (https://infomeddnews.com/menarini-group-presented-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-patients-with-er-her2-metastatic-breast-cancer-m)
   • forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/mZK974Whp6cPoyqLM/the-relative-ethicalness-of-clinical-trial-designs)
   • theepochtimes.com (https://theepochtimes.com/world/most-decisions-to-approve-or-reject-new-drugs-based-on-poor-clinical-data-study-suggests-5587082?utm_medium=social&utm_source=twitter&utm_campaign=digitalsub)
2. Characteristics of Effective Endpoints
   • forum.effectivealtruism.org (https://forum.effectivealtruism.org/posts/mZK974Whp6cPoyqLM/the-relative-ethicalness-of-clinical-trial-designs)
   • hitconsultant.net (https://hitconsultant.net/2023/11/21/clinical-trial-data-strategy-shifting-to-innovative-data-collection)
   • fda.gov (https://fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials?utm_content=bufferf9e54&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer)
   • fda.gov (https://fda.gov/news-events/press-announcements/fda-issues-draft-guidance-conducting-multiregional-clinical-trials-oncology)
   • news-medical.net (https://news-medical.net/news/20240925/WHO-issues-new-guidance-to-enhance-clinical-trials-worldwide.aspx)
   • aakinshin.net (https://aakinshin.net/posts/cs-social-survey)
   • clinicaltrialsarena.com (https://clinicaltrialsarena.com/sponsored/how-electronic-clinical-outcome-assessments-improve-clinical-trial-evidence-generation)
3. Types of Endpoints: Direct, Surrogate, and Composite
   • dontforgetthebubbles.com (https://dontforgetthebubbles.com/poos-loos-doos-and-moos)
   • statnews.com (https://statnews.com/pharmalot/2024/09/12/moderna-lilly-gsk-astrazeneca-antibiotics-inhalers-antimicrobials-monkeys-fda-abbvie-migraine-roche-obesity-weight-novo?utm_campaign=rss)
   • fda.gov (https://fda.gov/about-fda/center-drug-evaluation-and-research-cder/completed-research-projects-office-prescription-drug-promotion-opdp-research)
   • pfizer.com (https://pfizer.com/news/press-release/press-release-detail/pfizer-presents-positive-data-phase-2-study-ponsegromab)
   • fda.gov (https://fda.gov/about-fda/center-drug-evaluation-and-research-cder/completed-research-projects-office-prescription-drug-promotion-opdp-research)
4. Commonly Used Endpoints in Clinical Trials
   • nature.com (https://nature.com/articles/s41571-023-00823-5)
   • sensible-med.com (https://sensible-med.com/p/how-authors-choices-affect-how-evidence?r=1mem2&utm_campaign=post&utm_medium=web)
   • clinicaltrialsarena.com (https://clinicaltrialsarena.com/sponsored/how-electronic-clinical-outcome-assessments-improve-clinical-trial-evidence-generation)
   • fda.gov (https://fda.gov/about-fda/center-drug-evaluation-and-research-cder/completed-research-projects-office-prescription-drug-promotion-opdp-research)
   • raps.org (https://raps.org/News-and-Articles/News-Articles/2024/6/Stakeholders-request-elaboration,-consistency-in-F?utm_campaign=regulatory-focus&utm_source=twitter&utm_medium=social)
5. Challenges in Selecting Primary Endpoints
   • news-medical.net (https://news-medical.net/news/20240925/WHO-issues-new-guidance-to-enhance-clinical-trials-worldwide.aspx)
   • fda.gov (https://fda.gov/news-events/fda-voices/increasing-options-clinical-research-facilitate-medical-product-development)
   • nature.com (https://nature.com/articles/s41392-024-01760-0)
   • hbiostat.org (https://hbiostat.org/proj/covid19/statdesign#fundamental-elements-of-outcome-assessments)
   • bmj.com (https://bmj.com/content/385/bmj-2023-078000?utm_campaign=usage&utm_content=tbmj_sprout&utm_id=BMJ005&utm_medium=social&utm_source=twitter)
   • rethinkingclinicaltrials.org (https://rethinkingclinicaltrials.org/news/grand-rounds-june-14-2024-dapa-mi-a-pragmatic-registry-based-double-blind-rct-trial-designed-for-regulatory-evaluation-stefan-james-jonas-oldgren)
   • link.springer.com (https://link.springer.com/article/10.1007/s11136-023-03587-8)
   • bmj.com (https://bmj.com/content/386/bmj-2023-078525?utm_campaign=usage&utm_content=tbmj_sprout&utm_id=BMJ005&utm_medium=social&utm_source=twitter)
   • Accelerating clinical trials to improve biopharma R&D productivity (https://mckinsey.com/industries/life-sciences/our-insights/accelerating-clinical-trials-to-improve-biopharma-r-and-d-productivity)
6. Statistical Considerations in Endpoint Selection
   • onlinelibrary.wiley.com (https://onlinelibrary.wiley.com/journal/10970258)
   • arxiv.org (https://arxiv.org/abs/2311.16506)
   • fda.gov (https://fda.gov/drugs/regulatory-science-action/adaptive-trial-design-testing-bioequivalence-generics-highly-variable-drugs)
   • sensible-med.com (https://sensible-med.com/p/doing-statistics-can-be-difficult)
   • news-medical.net (https://news-medical.net/news/20240925/WHO-issues-new-guidance-to-enhance-clinical-trials-worldwide.aspx)
7. Case Study: Successful Endpoint Selection in Practice
   • news.abbvie.com (https://news.abbvie.com)
   • infomeddnews.com (https://infomeddnews.com/menarini-group-presented-initial-safety-and-efficacy-data-from-phase-1b-2-elevate-and-electra-combination-studies-of-orserdu-elacestrant-in-patients-with-er-her2-metastatic-breast-cancer-m)
   • globenewswire.com (https://globenewswire.com/news-release/2024/09/12/2945039/0/en/Fulcrum-Therapeutics-Announces-Topline-Results-from-Phase-3-REACH-Clinical-Trial-of-Losmapimod-in-Facioscapulohumeral-Muscular-Dystrophy-FSHD.html)
   • ajkdblog.org (https://ajkdblog.org/2024/09/11/translation-of-clinical-trial-outcomes-into-real-clinical-practice-an-interview)
   • dontforgetthebubbles.com (https://dontforgetthebubbles.com/poos-loos-doos-and-moos)
   • jamanetwork.com (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2814216)
   • journals.sagepub.com (https://journals.sagepub.com/author-instructions/CTJ#ArticleTypes)
   • fda.gov (https://fda.gov/regulatory-information/search-fda-guidance-documents/use-data-monitoring-committees-clinical-trials?utm_content=bufferf9e54&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer)
   • nlm.nih.gov (https://nlm.nih.gov/pubs/techbull/mj24/mj24_Clinical_Trials_Study_Record_Modernization.html)

Introduction

The International Classification of Functioning, Disability, and Health (ICF) is a vital tool in the healthcare and clinical trials field. Developed by the World Health Organization, the ICF offers a universal language and structure for documenting health and health-related states. It goes beyond simply cataloging ailments and evaluates the broader impact of health conditions on an individual’s daily life, assessing their functional capabilities and societal involvement.

In contrast to the International Statistical Classification of Diseases and Related Health Problems (ICD), the ICF complements it by contextualizing the consequences of health conditions on individuals’ lives. Together, these classification systems provide a holistic view of health, enhancing our understanding of health trends and enabling better healthcare delivery tailored to the diverse needs of patients. In this article, we will explore the origin and development of the ICF, its components, its application in healthcare, its role in clinical trials, and the benefits it brings to both fields.

What is ICF?

The is an integral part of the healthcare and lexicon. Created by the World Health Organization, the ICF offers a global language and framework for the documentation of and conditions related to . Its purpose extends beyond documenting ailments; it evaluates the wider impact of on an individual’s daily life, assessing their and societal involvement. This comprehensive approach to reflects the complex interplay of various factors, including genetic makeup, environmental influences, and personal experiences, which collectively shape an individual’s .

In contrast to the ICF’s emphasis on functionality, the and Related Problems (ICD), specifically the latest ICD-11 version effective from January 2022, serves as a global data standard for recording and analyzing disease and mortality data. While the ICD is pivotal for producing standardized health statistics, guiding diagnoses, and supporting management of , the ICF complements it by contextualizing the consequences of on individuals’ lives. Collectively, these categorization systems provide a comprehensive perspective on , improving our comprehension of patterns and facilitating superior medical provision customized to the varied requirements of individuals.

Origin and Development of ICF

The inception of the , Disability, and Health (ICF) in the early 2000s marked a significant evolution from the previous International Classification of Impairments, Disabilities, and Handicaps (ICIDH). With an aim to adopt a more integrated and comprehensive framework for classification, the ICF was cultivated through rigorous research and the concerted efforts of a diverse group of experts. This group encompassed . They worked together to build a tool that would improve the comprehension and monitoring of well-being and disability at both individual and population levels. The ICF’s development mirrors the meticulous process undertaken for the and Related Problems (ICD), a global standard for recording and statistics, which has been foundational in providing consistent and comparable data for over a century. The ICF, similar to the latest ICD-11, aims to facilitate the systematic recording, analysis, and interpretation of information, transcending language and cultural barriers to achieve a universal standard. This aligns with the World Organization’s mandate for a complete data standard, ensuring interoperability and utility across various domains, from to resource allocation.

Components of ICF

The International Classification of Functioning, Disability and (ICF) model is a dual-component system designed to capture an in-depth picture of an individual’s physical and mental condition and its impact on day-to-day life. The first component, , encompasses Body Functions and Body Structures, as well as an individual’s Activities and Participation. This aspect of the model provides insights into the of various conditions, alongside the practical implications on a person’s ability to engage in life situations.

The second component, , is further divided into Environmental Factors and Personal Factors. These factors collectively account for the role of the physical, social, and attitudinal environment in which people live and conduct their lives. They serve as an integral part of the model, recognizing that disability and functioning do not exist in isolation but are influenced by a broader context. This approach mirrors the multi-faceted nature of , as per statistics which highlight that is not merely about the absence of disease but involves a complex interplay of genetic, psychological, and environmental factors.

Essentially, the corresponds to the recognition that and the effectiveness of interventions result from both individual traits and the support systems accessible, as highlighted by recent efforts in and the incorporation of novel technologies in medical settings.

Application of ICF in Healthcare

The implementation of the , Disability and Health (ICF) has transformed the provision of , providing a standardized framework to assess and record individual functioning and disability. Healthcare professionals utilize ICF to meticulously identify areas of patient concern, facilitating the creation of tailored intervention strategies. This fosters a , prioritizing personal objectives and values. Concurrently, the , including big data and artificial intelligence, is reshaping the delivery of , paving the way for more efficient, and teledentistry. This in the medical field supports a more nuanced application of ICF, enhancing the precision and personalization of . As the medical sector keeps progressing, the combination of ICF’s extensive evaluation tools with state-of-the-art digital medical solutions offers the potential to enhance the influence on patient results and medical efficiency.

ICF in Clinical Trials

The , Disability, and Health (ICF) serves as a universal framework in trials to describe and measure . By employing the ICF, researchers gain the ability to convey the effects of healthcare interventions on an individual’s functional status and societal involvement with precision. This promotes the synthesis of research outcomes, enhancing the comparability of studies across various conditions and interventions. This is especially apparent in research on , such as AI-driven predictions of individual drug responses in oncology, where outcomes are intricately related to patient-specific factors. For example, in precision oncology trials, matching scores based on drug sensitivity assays are utilized to correlate the alignment of prescribed treatments with AI recommendations, significantly impacting patient prognosis in conditions like B-cell lymphoma. Moreover, the ICF’s comprehensive approach allows for the assessment of interventions through both the (QALY) metric and the Equal Value of Life Years Gained (evLYG), providing a holistic view of the intervention’s impact on life length and quality. The integration of patient and public involvement in trial design, as endorsed by international bodies, further emphasizes the importance of aligning research with , ensuring that the findings resonate with the needs and experiences of those affected. Basically, ICF’s role extends beyond measurement to inform decision-making and policy development, aligning with the FDA’s initiatives to harmonize human subject protection regulations and enhance the efficiency of research.

Benefits of Using ICF in Healthcare and Clinical Trials

The application of the in the domain of medical care and trials is crucial for improving patient care and progressing medical research. ICF’s framework excels in fostering uniformity in communication among healthcare providers and researchers, which is paramount for collaborative efforts. For example, the use of artificial intelligence (AI) to analyze unstructured medical notes demonstrates the incorporation of technological advancements with ICF’s standardized vocabulary, enhancing patient treatment plans and potentially prolonging life expectancies in conditions like uveal melanoma metastasis to the liver, for which research studies are a vital pathway due to the lack of .

Moreover, ICF’s holistic approach to health assessment recognizes the intricate interplay between biological and psychosocial factors, thereby ensuring that treatment strategies are not only personalized but also aligned with the individual’s unique health profile. This methodology is supported by emerging AI tools like the HINT algorithm and SPOT system, which aid in predicting trial outcomes and refining trial designs to enhance efficacy.

Additionally, the integration of ICF in research enables the consolidation and comparison of data across studies, thereby facilitating the emergence of . This is especially relevant when considering the utilization of quality-adjusted life years (QALYs) in cost-effectiveness analyses, which have become a cornerstone in evaluating the impact of medical interventions on patient outcomes.

The adoption of ICF is further underscored by the evolving landscape of (RWD) quality assessment, as highlighted by the FDA’s encouragement of incorporating RWD for more representative trial designs. The discussion about data quality and the appropriate use of RWD for trials are crucial in shaping patient-centric research methodologies.

Essentially, the ICF framework is a driver for innovation in the medical field, optimizing and propelling the advancement of research methodologies that are both effective and adherent to regulatory standards. It plays a critical role in the curation of a more robust, efficient, and patient-focused healthcare system, ultimately contributing to the betterment of clinical outcomes.

Conclusion

In conclusion, the International Classification of Functioning, Disability, and Health (ICF) is a vital tool in healthcare and clinical trials. Developed by the World Health Organization, it provides a universal language and structure for documenting health and health-related states. The ICF goes beyond cataloging ailments and evaluates the broader impact of health conditions on daily life, assessing functional capabilities and societal involvement.

It complements the International Statistical Classification of Diseases and Related Health Problems (ICD), offering a holistic view of health and enhancing healthcare delivery tailored to diverse patient needs.

The ICF’s origin and development involved collaboration among healthcare professionals, researchers, and individuals with firsthand experience of disability. It aims to facilitate the systematic recording, analysis, and interpretation of health information on a universal scale. The ICF model consists of two components: Functioning and Disability, which encompass Body Functions, Body Structures, Activities, and Participation; and Contextual Factors, which include Environmental Factors and Personal Factors.

This comprehensive framework recognizes the multi-faceted nature of health and the influence of a broader context on disability and functioning.

In healthcare, the ICF revolutionizes patient care by delivering a standardized framework to evaluate and document individual functioning and disability. Integration with Medical 4.0 technologies enhances the precision and personalization of patient care. In clinical trials, the ICF serves as a universal framework to describe and measure health and disability levels, promoting research outcome synthesis, comparability across studies, and assessment of interventions.

The benefits of using the ICF in healthcare and clinical trials are significant. It fosters uniformity in communication, supports personalized treatment strategies, enables data consolidation and comparison, and contributes to evidence-based practices. The integration of ICF in research methodologies aligns with the evolving landscape of real-world data quality assessment and patient-centric research.

Overall, the ICF is a catalyst for innovation in healthcare, optimizing patient-centered care, and propelling the development of effective research methodologies. Its comprehensive approach to health assessment plays a critical role in curating a robust, efficient, and patient-focused healthcare system, ultimately contributing to better clinical outcomes.

Contact bioaccess™ for expert guidance on implementing the ICF framework in your healthcare practice and revolutionize patient care.

Frequently Asked Questions

What is the International Classification of Functioning, Disability, and Health (ICF)?

The ICF is a framework developed by the World Health Organization to document and evaluate well-being and medical conditions. It assesses the impact of medical conditions on an individual’s daily life, focusing on functional capabilities and societal involvement.

How does the ICF differ from the International Statistical Classification of Diseases and Related Problems (ICD)?

While the ICF emphasizes functionality and the broader impact of health conditions on individuals’ lives, the ICD, particularly the latest ICD-11 version, serves as a global standard for recording and analyzing disease and mortality data. The ICF complements the ICD by providing context about how medical conditions affect daily functioning.

When was the ICF developed, and what prompted its creation?

The ICF was developed in the early 2000s as an evolution from the previous International Classification of Impairments, Disabilities, and Handicaps (ICIDH). Its creation involved extensive research and collaboration among healthcare professionals, researchers, and individuals with disabilities to create a more integrated and comprehensive classification system.

What are the two main components of the ICF model?

The ICF model consists of two main components: Functioning and Disability, which includes Body Functions and Structures, as well as Activities and Participation; and Contextual Factors, which is further divided into Environmental Factors and Personal Factors, recognizing the influence of various contexts on disability and functioning.

How does the ICF framework support healthcare professionals?

The ICF provides a standardized framework for assessing and recording individual functioning and disability. This allows healthcare professionals to identify patient concerns accurately and develop tailored intervention strategies that prioritize personal objectives and values.

In what ways is the ICF utilized in clinical trials?

The ICF offers a universal framework for describing and measuring health and disability levels in research. It allows researchers to convey the effects of healthcare interventions on an individual’s functional status, enhancing the comparability of studies and promoting patient-centered outcomes.

How does the integration of technology with the ICF enhance patient care?

The integration of Medical 4.0 technologies, such as artificial intelligence and big data, with the ICF framework improves the precision and personalization of patient treatment plans. These advancements support a holistic approach to health assessment and optimize patient-centered care.

What is the significance of quality-adjusted life years (QALY) in the context of the ICF?

The ICF framework allows for the assessment of health interventions using metrics like QALY, which provides a comprehensive view of an intervention’s impact on both life expectancy and quality of life, reinforcing the importance of patient-centered research.

How does the ICF contribute to evidence-based practices in healthcare?

By facilitating data consolidation and comparison across studies, the ICF supports the emergence of evidence-based practices. This is particularly important in the evaluation of medical interventions and the incorporation of real-world data in trial designs.

Why is the ICF considered essential for the future of healthcare and research?

The ICF promotes a more robust and patient-focused healthcare system by optimizing care delivery and advancing research methodologies. It aligns with regulatory standards, ensuring that healthcare interventions are effective and responsive to patient needs.

List of Sources

1. What is ICF?
   • who.int (https://who.int/classifications/classification-of-diseases)
   • nihcm.org (https://nihcm.org/publications/supporting-the-health-care-needs-of-people-with-disabilities)
   • qualitysafety.bmj.com (https://qualitysafety.bmj.com/content/33/3/152)
   • abs.gov.au (https://abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey/2022)
   • internetcomputer.org (https://internetcomputer.org/how-it-works/chain-key-technology)
   • medium.com (https://medium.com/dfinity/the-future-of-it-secure-compute-without-cybersecurity-9c0e6c8e65b1)
2. Origin and Development of ICF
   • medium.com (https://medium.com/dfinity/how-ckbtc-solves-the-dilemma-of-blockchain-bridges-ee8e0b72ee59)
   • medium.com (https://medium.com/dfinity/the-future-of-it-secure-compute-without-cybersecurity-9c0e6c8e65b1)
   • who.int (https://who.int/classifications/classification-of-diseases)
   • medium.com (https://medium.com/dfinity/red-pill-blue-pill-the-hidden-history-of-the-internet-computer-and-why-it-will-win-f9a3bd0cc72b)
   • ai-case-study.vercel.app (https://ai-case-study.vercel.app)
   • who.int (https://who.int/classifications/classification-of-diseases)
3. Components of ICF
   • digitalregulations.innovation.nhs.uk (https://digitalregulations.innovation.nhs.uk/case-studies/using-a-chatbot-to-ease-staff-shortages-and-improve-patient-care)
   • abs.gov.au (https://abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey/2022)
   • sites.ed.gov (https://sites.ed.gov/idea/idea-files/policy-statement-inclusion-of-children-with-disabilities-in-early-childhood-programs?utm_content=&utm_medium=email&utm_name=&utm_source=govdelivery&utm_term=)
   • ada.gov (https://ada.gov/resources/olmstead-employment-qa)
   • digitalhealth.net (https://digitalhealth.net/2023/11/digital-health-coffee-time-briefing-21)
   • med-technews.com (https://med-technews.com/news/latest-medtech-events-and-expo-news/healthcare-innovation-consortium-to-launch-programme-to-help)
   • digitalhealth.net (https://digitalhealth.net/2023/11/nhs-education-for-scotland-collaborates-for-future-workforce-development)
   • internetcomputer.org (https://internetcomputer.org/how-it-works/chain-key-technology)
   • internetcomputer.org (https://internetcomputer.org/what-is-the-ic)
   • docs.nfid.one (https://docs.nfid.one/vaults/overview)
   • who.int (https://who.int/classifications/classification-of-diseases)
4. Application of ICF in Healthcare
   • digitalregulations.innovation.nhs.uk (https://digitalregulations.innovation.nhs.uk/case-studies/using-a-chatbot-to-ease-staff-shortages-and-improve-patient-care)
   • vph-institute.org (https://vph-institute.org/news/the-innovative-health-initiative-ihi-current-and-future-call-topics.html|)
   • igi-global.com (https://igi-global.com/chapter/adopting-artificial-intelligence-in-healthcare/333956)
   • nitorinfotech.com (https://nitorinfotech.com/blog/cloud-computing-unlocking-its-potential-in-healthcare?utm_source=socialmedia&utm_medium=linkedin&utm_campaign=blog)
5. ICF in Clinical Trials
   • imprimedicine.com (https://imprimedicine.com/updates/imprimed-ai-for-dogs-with-relapsed-lymphomas)
   • implementationsciencecomms.biomedcentral.com (https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-024-00635-3)
   • icr.ac.uk (https://icr.ac.uk/news-archive/trial-results-support-new-gold-standard-for-head-and-neck-cancer-radiotherapy?utm_source=twitter&utm_medium=organic&utm_campaign=edtl&utm_content=23135)
   • ncbi.nlm.nih.gov (https://ncbi.nlm.nih.gov/pmc/articles/PMC11017749)
   • icer.org (https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg)
   • fda.gov (https://fda.gov/news-events/fda-voices/increasing-options-clinical-research-facilitate-medical-product-development)
   • fda.gov (https://fda.gov/drugs/news-events-human-drugs/evolving-role-decentralized-clinical-trials-and-digital-health-technologies)
   • fortrea.com (https://fortrea.com)
   • news.abbvie.com (https://news.abbvie.com)
   • nimml.org (https://nimml.org/news/detail/nimml-announces-positive-results-of-omilancor-clinical-trials-in-ulcerative)
   • pmlive.com (https://pmlive.com/pharma_news/icr_study_increases_understanding_of_advanced_breast_cancer_complication_1505276)
6. Benefits of Using ICF in Healthcare and Clinical Trials
   • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/scope-2024-alex-deyle-of-flatiron-health-discusses-rwd-in-clinical-trials)
   • hitconsultant.net (https://hitconsultant.net/2023/12/20/how-intelligent-document-processing-idp-revolutionizes-clinical-trials)
   • ir.icumed.com (https://ir.icumed.com/news-releases/news-release-details/icu-medical-announces-fourth-quarter-2023-results-and-provides)
   • icer.org (https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg)
   • fusfoundation.org (https://fusfoundation.org/diseases-and-conditions)
   • infomeddnews.com (https://infomeddnews.com/inspire-icu-1-clinical-trial-in-the-us)
   • medicalplasticsnews.com (https://medicalplasticsnews.com/news/medical-plastics-company-news/mft-awarded-£2-5m-to-lead-national-research)
   • pmlive.com (https://pmlive.com/pharma_news/icr_experts_develop_clinical_trial_guidelines_to_support_future_research_1502896)
   • medcitynews.com (https://medcitynews.com/2023/10/how-ai-can-fix-the-broken-clinical-trial-process)
   • nature.com (https://nature.com/articles/d41586-024-00753-x)
   • who.int (https://who.int/classifications/classification-of-diseases)
   • bmj.com (https://bmj.com/content/384/bmj-2023-076316?utm_campaign=usage&utm_content=tbmj_sprout&utm_id=BMJ005&utm_medium=social&utm_source=twitter)